METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA

Clinical trials for METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA trials appear

Sign up with your email to follow new studies for METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare cancers: Triple-Threat therapy trial opens

Disease control Recruiting now

This study is testing a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—for patients with rare types of bladder, kidney, penile, and other urinary tract cancers that have spread. The goal is to see if this three-drug approach can shrink tumors and control the d…

Matched conditions: METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 24, 2026 12:01 UTC

METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA

Get alerted when new METASTATIC BLADDER CLEAR CELL (GLYCOGEN-RICH) UROTHELIAL CARCINOMA trials appear

New hope for rare cancers: Triple-Threat therapy trial opens